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March 2014 registry including definitions of clinical variables used have been described previously. 14, 15 The National Institutes of Health Stroke Scale (NIHSS) was assessed on admission and at discharge from the stroke unit. The modified Rankin Scale (mRS) was assessed by a 3-month follow-up call. We defined mild deficit as a score in the NIHSS of ≤5 points in accordance with previous studies. 9, 13, [16] [17] [18] With regard to thrombolysis, parameters of the database and markers of quality were defined in 2002. Patients with intra-arterial thrombolysis were excluded from this analysis. Symptomatic intracerebral hemorrhage (SICH) was rated according to National Institute of Neurological Disorders and Stroke criteria (any CT-or MRI-documented bleeding with clinical deterioration of ≥1 point on the NIHSS or leading to death <7 days). 19 The ASUR is part of a governmental quality assessment program for stroke care in Austria financed by the Federal Ministry of Health. It is based on the federal law promoting quality in health (Gesundheitsqualitätsgesetz) . Anonymized data are centrally administered by Gesundheit Österreich GmbH, and scientific analyses are approved and supervised by an academic review board.
Matching
Patients with mild deficit with and without intravenous rt-PA treatment were matched according to sex, prestroke disability (according to mRS), stroke severity at baseline (according to NIHSS), age, hypertension, diabetes mellitus, hypercholesterolemia, stroke cause (according to the Trial of Org 10172 in Acute Stroke Treatment criteria), 20 and clinical stroke syndrome (according to the Bamford scale). 21 Overall, we tolerated a maximum deviation of 0.5 SD. This resulted in a median absolute deviation of 1.6 years for age. For severity (NIHSS), we enforced exact matching from 0 to 5. All other variables were available on a nominal (sex, hypertension, diabetes mellitus, hypercholesterolemia, cause, clinical syndrome) or ordinal (prestroke disability) level of measurement, and exact matching was required. To put these results into context, we repeated the analysis for the entire range of stroke severity following the same matching criteria and created a color-coded map on the basis of numbers need to treat, including all severity-age combinations. Again, we enforced for severity exact matching from 0 to 5 points of the NIHSS; starting from 6 points, we allowed a deviation proportional to the square root of the NIHSS score. A detailed description of data visualization is given in the online-only Data Supplement.
Statistics
For each matched pair, the treatment effect, E, was defined as 0 if both patients had the same mRS score at 3-month follow-up; 1 if the patient who received therapy with intravenous rt-PA had a worse outcome compared with the patient without rt-PA; and −1 if the patient who received intravenous rt-PA was better off. This definition is equivalent to the difference mRS treated -mRS control trimmed to the interval [−1,1] and ensures robustness and interpretability. For sensitivity analysis, we recalculated the same analysis using the NIHSS at the time point of discharge from stroke unit in patients with/without rt-PA treatment. Odds ratios (ORs) together with confidence intervals (CIs) comparing the mRS scores were derived from proportional odds logistic regression models taking ordinal mRS as target variable and rt-PA treatment as explanatory variable. For group comparisons of ordinal variables (such as the mRS), the paired Wilcoxon test for matched pairs was used. All data were processed using the statistical environment R, version 2.15.2.
Results

Baseline
Between March 2003 and April 2013, 54 917 adult patients with acute IS were included into the ASUR. Overall, 7509 patients received rt-PA treatment. Of those, 2109 presented with mild deficit defined as a NIHSS of ≤5 points. Information on 3-month functional outcome according to the mRS was available in 813 patients with mild deficit. The predefined matching algorithm allowed us to match 445 patients with rt-PA treatment to 445 patients without rt-PA treatment (Table) . rt-PA-treated patients with and without 3-month follow-up were comparable in terms of age, sex and stroke severity at baseline ( Table I in the online-only Data Supplement). The median onset-to-door time among matched patients with mild deficit who received rt-PA treatment was shorter (80 versus 175 minutes; interquartile range, 55-120 versus 80-482 minutes). The door-to-needle time among patients with rt-PA treatment was 49 (interquartile range, 35-70) minutes. SICH was more frequent in rt-PA-treated patients with mild deficit; among patients with mild deficit, 11 SICH (2.5%) occurred in those treated with rt-PA, whereas no SICH occurred in patients without rt-PA treatment; the occurrence of SICH increased with higher scores in the NIHSS (data not shown).
Outcome
We detected an improved outcome in rt-PA-treated patients with mild deficit compared with matched cases without rt-PA treatment. In 41%, the rt-PA-treated case had a better functional outcome at 3 months compared with the untreated case; in 29%, the case without rt-PA treatment was better off, and 30% of matched cases had the same mRS at 3 months. The distribution of matched patients with mild deficit according to increments of the mRS at 3 months is given in Figure 1 . We detected a shift toward improved outcome in patients with rt-PA treatment (OR, 1.49; 95% CI, 1.17-1.89; P<0.001).
To clarify whether there exists a specific cut-off point on the NIHSS at baseline to predict improvement in patients with mild deficit, we performed a post hoc analysis of the treatment effect of rt-PA according to increments on the NIHSS at baseline ( Figure I in the online-only Data Supplement). We detected a significant benefit in favor of rt-PA treatment in patients with 4 and 5 points on the NIHSS at baseline (OR, 1.94; 95% CI, 1.22-3.09; P=0.004; and OR, 1.51; 95% CI, 0.99-2.32; P=0.025, respectively). For patients with <4 points on the NIHSS at baseline, we did not detect a significant effect of rt-PA treatment. Sensitivity analysis using the NIHSS at discharge as alternative end point revealed similar results (data not shown).
Sensitivity analysis excluding patients without known onset-to-door time did not qualitatively change the results of the main analysis ( Figure II in the online-only Data Supplement).
To allow for comparisons of patients with mild deficit and patients with more severe strokes, we added rt-PA-treated patients with NIHSS >5 points using the same selection criteria and matched them to patients without rt-PA treatment following the same matching algorithm. Overall, in 3512 matched patients, rt-PA treatment was associated with improved functional outcome at follow-up. We detected a shift in the mRS toward improvement with thrombolysis at 3-month follow-up (OR, 1.52; 95% CI, 1.35-1.71). Data visualization using color mapping showed that in rt-PA-treated patients with mild deficit, effect sizes were smaller than in patients with scores >5 points in the NIHSS but still ranged between numbers need to treat of 8 to 14 (Figure 2) . Notably, in patients with mild deficit, improvement achieved by rt-PA treatment was observed along the entire age range and was also detectable in a substantial proportion of elderly patients between 80 and 90 years. However, we were lacking sufficient numbers of pairs to depict differences for patients with NIHSS <2 points and for patients aged >90 years.
Discussion
This is the largest observational study published to date suggesting rt-PA treatment to be effective in patients with mild deficit. Of note, improvement achieved by rt-PA treatment was visible anlong the entire age rage including a substancial proportion of very elderly patients.
Better functional outcome in cases treated with rt-PA was opposed by a higher rate of SICH. However, rates of SICH were overall low independently of rt-PA treatment. Above 3 points in the NIHSS, we detected a robust benefit of rt-PA treatment. This result was supported by a sensitivity analysis using the NIHSS at discharge as outcome parameter. Below 4 points, we were lacking the power to detect an association of intravenous rt-PA treatment with outcome. Therefore, we could neither infer nor rule out that certain subgroups of patients with NIHSS <4 points benefit from thrombolytic treatment. For such treatment decisions, multimodal MRI might serve as a useful tool in the future. 22 Moreover, selection by specific syndromes, such as isolated aphasia, might enable better selection of potential candidates for rt-PA treatment in patients with NIHSS <4 points. 23 Previous data from randomized studies 9,10 and observational cohorts 12, 13, 16, 24 reported conflicting results with regard to the efficacy of rt-PA treatment in patients with mild stroke. 
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Overall, the interpretation of these data is difficult, because different cut-off points on the NIHSS have been used to define the term mild deficit. For our study, we predefined the term mild deficit in accordance with IST-3 and other recently published studies. 9, 13, [16] [17] [18] The number of patients with mild deficit subsequently having poor outcome is substantial in our data, but in line with the literature. [6] [7] [8] [9] Previous studies found subgroups of patients with mild stroke at particular risk of adverse functional outcome. This does include patients with proximal vessel occlusions, 25 those with complete homonymous hemianopia, 26, 27 and those presenting with early neurological worsening (frequently seen in patients with capsular warning syndrome) 28 or worsening due to intercurrent diseases. In addition, adverse outcome in mild stroke could be related to inadequate detection of functional impairment (eg, due to cognitive deficits or neuropsychological symptoms) by the NIHSS. 7 With regard to the vessel status, systematic implementation of computed tomography angiography was not possible in the ASUR; therefore, we are unable to provide numbers of vessel occlusions. However, a significant association has been reported between the NIHSS score and detection of proximal vessel occlusions in other studies. 29, 30 As we matched for the baseline NIHSS, it was unlikely that differences in the occurrence of proximal occlusions influenced our results. We also matched for stroke syndrome, making it unlikely that differences between patients with and without rt-PA treatment were caused by different numbers of lacunar strokes or strokes in the posterior cerebral artery. Interestingly, patients with and without rt-PA treatment improved in the NIHSS until discharge from the stroke unit. In other words, the detected differences in the 3 months functional outcome seem to be caused by lesser improvement in non rt-PA treated patients and not by increased rates of worsening. In addition, with the exception of SICH, the numbers of complications were equally distributed between patients with mild deficit with and without thrombolytic treatment ( Table II in the online-only Data Supplement).
Limitations
Data collected in registries do not compensate for randomized studies, because the occurrence of selection bias cannot be excluded. However, because immediate entry of patients into the ASUR is mandatory and the registry is part of a governmental quality assessment program, we can assume that the vast majority of patients undergoing rt-PA treatment are included into the registry. Data on functional outcome at 3 months were available in a restricted number of patients. Difficulties in the ascertainment of follow-up data originating from hospital-based multicenter registries are a common problem. 6 In our data, patients with and without data on functional outcome at follow-up were comparable in relation to age, sex, and rate of rt-PA treatment. Moreover, the analysis using the NIHSS at discharge from the stroke unit as an alternative end point supported the results. NIHSS scores at discharge from the stroke unit were available for 91% of included patients.
Conclusions
This study provides evidence of a beneficial effect of intravenous rt-PA for patients with mild stroke in the largest cohort of patients analyzed to date. Although our data have to be regarded as exploratory, the large number of patients included in the ASUR allowed exact matching of a large number of risk factors and outcome-associated factors. This allowed the analysis of 2 highly comparable patient groups and makes our main results robust. Furthermore, it facilitated better estimation of treatment effects across different age groups and different grades of severity. Our results suggest that randomized controlled studies of rt-PA treatment in patients with mild IS are warranted. At the same time, our data indicate that the expected absolute benefit from thrombolysis in patients with mild deficit might be rather small. Therefore, given the large sample sizes needed, this will constitute a major challenge for the implementation and completion of future randomized controlled trials such as the Potential for rt-PA to Improve Strokes with Mild Symptoms (PRISMS) trial, which is currently being planned. 31 This further underscores the importance of data originating from large registries at the current stage. 
Disclosures
